Objective: Zonisamide is an antiepileptic drug with a perspective of a broader use. Although it is regarded as a relatively safe drug, zonisamide might cause disorders of the central nervous system. The study assessed the influence of zonisamide on spatial and emotional memory in adult Wistar rats. Methods: Morris water maze test was used to examine the effect of zonisamide administered p.o. as single dose (50 mg/kg or 100 mg/kg) or repeatedly (50 mg/kg) on spatial memory. The impact of zonisamide administered as above on emotional memory was assessed in the Passive avoidance test. Results: Zonisamide mainly in a high acute dose impaired the spatial memory, whereas when administered repeatedly, its effect was observed only in the initial phase of the study. Emotional memory disturbances were noted only during repeated administration of zonisamide. Conclusion: Zonisamide may impair memory and learning processes in rats but the results are varied and depend on the type of memory.
Introduction
Zonisamide is a novel antiepileptic drug. Initially registered only as a drug in add-on treatment of partial seizures, it is now used in monotherapy of focal seizures in newly diagnosed adults and for adjunctive therapy in adults and children over six years old in Europe. In Japan, zonisamide is used for generalized and focal seizures, both in monotherapy and as adjunctive treatment in children and adults and has also been recommended for add-on therapy in Parkinson's disease since 2009 [1] . This beneficial effect of zonisamide is associated with a complex mechanism of action, which distinguishes it from other drugs representing this group. The drug blocks T-type calcium ion channels [2] and voltage-dependent sodium channels [3] . Zonisamide may indirectly contribute to the release of neurotransmitters by affecting the activity of calcium and sodium channels. It has also been demonstrated that the drug has a differential direct effect on the synthesis, release, and metabolism of GABA, glutamate [4] , dopamine [5] , and serotonin [6] , which leads to an increase of synaptic inhibition. However, the reports on these issues are divergent and currently there is no unambiguous opinion to what extent the impact of zonisamide on these neurotransmission systems determines its clinical effects. Zonisamide is also a weak inhibitor of carboanhydrase; however, this mechanism has no clinical significance [7] . Apart from the impact on ion channels and neurotransmitter systems, zonisamide has also neuroprotective activity [8, 9] .
Zonisamide is considered a relatively safe drug as compared with other antiepileptic drugs, and the results of clinical trials confirm its favorable safety profile. It has been demonstrated that the incidence of side effects was significantly lower among patients with epilepsy receiving zonisamide monotherapy than in those undergoing combination therapy. The most commonly reported adverse effects were disorders of the central nervous system including sleepiness, dizziness, irritability, ataxia, or depressive states [10] . However, because of its multidirectional mechanism of action, the efficacy of zonisamide is investigated in the treatment of bipolar disorder [11] , anxiety [12] , eating disorders [13, 14] , migraine [15] , and alcohol dependence [16] .
The perspective of a broader use of the drug requires more extensive research into its impact on cognitive processes. There is little information available in this area in the literature and it mostly refers to clinical trials involving small number of patients [16, 17] . Hence, the aim of the study was to assess the influence of zonisamide on spatial and emotional memory respectively in two behavioral models: Morris water maze (MWM) test and Passive Avoidance (PA) test.
Materials and methods

Animals
In this experiment, 88 adult male Wistar rats (Medical University of Bialystok, Poland) weighing 250-290 g were used. The animals were housed in normal laboratory conditions (20-22°C, 12:12 h light-dark cycle) with free access to water and commercial chow. The tests were performed between 9:00 a.m. and 4:00 p.m. during the light phase. The rats were divided into 4 groups in the MWM test (n = 8) and 8 Epilepsy & Behavior 102 (2020) 106659 groups in the PA test (n = 7). Because of the 3R principle, the number of animals was reduced, and rats exposed to a single low dose of zonisamide in the MWM test were included in the group receiving the drug repeatedly at an analogous dose.
The experiments were carried out in full compliance with Polish government regulations regarding experiments on animals (Dz. U.05.33.289). All experiment protocols were approved by the Local Ethical Committee for Animal Experimentation (resolution no. 50/ŁB/ 754/2015).
Drug
Zonisamide (Zonegran, Eisai®) was administered directly to the stomach via an oral gavage as a suspension in a 1% methylcellulose solution in the amount of 0.2 ml/100 g. The doses of zonisamide were selected based on available literature [18, 19] . To study the acute effect on memory processes, a single dose regarded as high (100 mg/kg) or low (50 mg/kg) was given 3 h before the trial. The start time of test was chosen based on C max and T max of zonisamide. The drug was administered repeatedly once a day at a dose of 50 mg/kg for 7 or 14 days to assess the effect of prolonged administration. In the MWM test, the drug was administered for 13 days before the first test day, while during the trials, the animals received the drug after the end of the test in order to avoid the impact of the acute dose on the results. In the PA, the drug was administered 7 or 14 days before the test (Fig. 1) . The control group received 1% aqueous solution of methylcellulose in the amount of 0.2 ml/100 g.
Morris water maze test (MWM)
The MWM consists of a circular pool (diameter 180 cm; walls 50 cm high) filled with water (22-24°C). The pool was placed in a room with several extra-maze cues and virtually divided into four sections. A transparent circular Plexiglas platform (diameter 8 cm) was used during the experiment. It was placed in the center of the selected quadrant about 2 cm below the surface of water and was invisible for animals.
The experiments were recorded with a camera installed above the pool, which allowed close monitoring of the test in real-time without eye contact between an animal and experimenter during the swimming phase. Rat position, movement and entrance to the platform were detected using ANY-maze software (ANY-maze, USA).
During the first three days of the experiment, the rats were pretrained to learn the mechanism of the experiment. The platform was placed in a selected quadrant before the animals were introduced.
Each time, the selected animal was put into the pool in a different quadrant, facing the wall, and allowed to swim for 60 s. If the rat managed to find the platform, it was allowed to stay on it for 15 s and observe the room. If the animal did not find the platform in 60 s, it was placed there manually by the experimenter for 15 s to observe the room. The experiment was repeated for each animal four times per day with 60-second intervals between the trials.
After the 3 pretraining days, the retention test was carried out, where an analogous scheme of the test was applied without the platform. During these trials, the animals spent more time swimming in the quadrant that previously contained the hidden platform. An inability to locate the platform in the memorized place caused the rats to search for it along the length of the entire pool. After the pretraining period, the platform was moved to another quadrant and the activities of days 1-3 were repeated [20] . The time required to find the platform, traveled distance, and percentage of time spent in the proximity of the platform were measured.
In those experiments assessing the prolonged administration of zonisamide, the above tests were performed for three consecutive days, but the drug was given only on the first and second test day. Zonisamide was not administered on the third test day in order to assess the effect of discontinuation of administration on following days. The lack of administration did not affect the results on the third day because the animals received the drug after the end of the test in order to avoid the impact of the acute dose on the results. In the "after-drug" period, the trials were performed after 48 h and 72 h after following administration of the last dose of the zonisamide (Fig. 1 ).
Passive avoidance (PA) test
The PA test is based on the natural desire of a rodent to remain in dark places. Animals learn to avoid specific compartment associated with an aversive stimulus. A step-through, light-dark apparatus (Gemini Avoidance System, San Diego, USA) was used to assess emotional memory in the experiment. The apparatus consisted of two compartments, 25 × 20 × 17 cm each, separated by a movable gate closing automatically when the animal passed into the second compartment.
An acquisition trial on the first day of the study introduced the rats to the experiment with a single test. There were seven animals in each group. The rats were put individually into a selected compartment and allowed to freely explore it for 60 s. The light was off and the gate was closed in this initial period. After this time, the light turned on and the gate opened simultaneously. The animal was able to move freely to the dark compartment. When the rat fully entered the dark compartment, the gate automatically closed and an electric foot shock (0.5 mA) was delivered through the grid floor for 3 s. The time taken to enter to the dark compartment was measured. After the shock, the animal remained there for approximately additional 15 s to associate an aversive stimulus with the environment. If the animal did not cross into the dark compartment within 300 s, it was excluded from the experiment [21] .
Twenty-four hours after the acquisition trial, each successful rat was subjected to a retention trial. That involved one trial run carried out identically to the acquisition trial except that no foot shock was generated when the animal passed into the dark compartment. The latency to enter the dark compartment was measured. The duration of the trial was 300 s maximum. If the animal did not enter the dark compartment within that time, it was returned to its home cage, and a latency of 300 s was recorded.
Statistical analysis
The normality of each distribution was checked by the KolmogorovSmirnov test, with Lilliefors correction. In the MWM, a statistical analysis was performed with the Kruskal-Wallis test (comparison between groups) and posthoc Friedman test (comparison within a group). In the PA, the Mann-Whitney U test was used to compare both groups, using the Statistica 12. A p-value of 0.05 or less indicated a statistically significant difference for all the statistical tests. Data are presented as mean values ± SD in the MWM and as median (horizontal bar), first and third quartiles (vertical column), and minimum and maximum (vertical line) in the PA.
Results
Initial training before zonisamide administration in the MWM
All the rats found the platform faster and traveled a shorter distance to find it each consecutive day of the training phase. As the experiment progressed, the time spent in the proper zone was prolonged (data not shown).
3.2. The effect of zonisamide administered at an acute dose of 100 mg/kg on spatial memory of rats in MWM Zonisamide administered at a single high dose (100 mg/kg) significantly prolonged the time required to find the platform ( Fig. 2A) and the traveled distance (Fig. 2B ). Significant differences between the groups were maintained throughout the entire duration of the study. During the following days of the experiment, a significant decrease of the time needed to find the platform was observed in the animals receiving the drug on the third trial day as compared both to the first and second test days. However, it was observed that the time was reduced significantly in the control group on the second and third test days as compared to the first test day (Fig. 2A) . In turn, a reduction of distance traveled in order to find the platform was noted between 2 and 3 test days in the animals receiving zonisamide. The distance traveled by the control group animals indicated a downward trend; however, there were no significant differences between specific test days (Fig. 2B) . Moreover, zonisamide also decreased the time spent in the zone with the platform as compared to the control group, and significant differences were observed on the second and third day of the experiment (Fig. 2C). 3.3. The effect of zonisamide administered at an acute dose of 50 mg/kg on spatial memory of rats in MWM Zonisamide administered at a single low dose (50 mg/kg) did not affect the length of the time needed to find the platform (Fig. 3A) , distance traveled to localize it (Fig. 3B) or the time spent in the proper zone with the platform (Fig. 3C) . It was observed that the time and distance required to find the platform had decreased gradually, whereas, the Fig. 2 . Effect of acute administration of 100 mg/kg zonisamide in MWM on the time needed to localize the platform (A), the distance traveled by rats in order to localize the platform -(B), the time spent in the zone with platform (C); ZN -zonisamide group; C -control group. time spent in the zone with the platform had extended as the experiment proceeded. However, those differences were not statistically significant.
The effect of zonisamide administered repeatedly at a dose of 50 mg/kg on spatial memory of rats in MWM
The rats that were administered zonisamide (50 mg/kg) for two weeks required more time to localize the platform (Fig. 4A) and traveled a longer distance to find it (Fig. 4B) than the animals representing the control group. However, it was a temporary effect because those parameters were observed to decrease already on the second day of the experiment when compared to the control group. No significant differences Fig. 3 . Effect of acute administration of 50 mg/kg zonisamide in MWM on the time needed to localize the platform (A), the distance traveled by rats in order to localize the platform -(B), the time spent in the zone with platform (C); ZN -zonisamide group; C -control group. Fig. 4 . Effect of repeated administration of 50 mg/kg zonisamide in MWM on the time needed to localize the platform (A), the distance traveled by rats in order to localize the platform -(B), the time spent in the zone with platform (C); ZN -zonisamide group; C -control group. between the groups were noted on the third test day. In addition, no significant differences between the groups were observed in the two subsequent days of the study on which the animals no longer received the drug (the "after-drug" phase).
In the following days of the study, a decrease of the time needed to find the platform was observed in the rats receiving zonisamide as compared to the first test day. In the control group, these significant decreases were noted only on the third and fifth test days (Fig. 4A) . Furthermore, a significant reduction of the traveled distance was observed on the second, third, and fifth test days in the zonisamide group and on third, fourth, and fifth test days in the control group (Fig. 4B) .
Moreover, prolonged administration of zonisamide caused the rats to spend significantly more time in the proximity of the platform on the second day of the study as compared to the control group (Fig. 4C) . No significant differences were observed between the groups on the remaining days of the experiment. As compared to the first test day, the increase of this time was observed in the zonisamide group on the second, third, and fifth test days. In addition, this increase was also noted in the control group on the fifth day as compared to the first and second test days.
The effect of zonisamide administered at an acute dose on emotional memory in the PA
Zonisamide administered at a single dose, both high (100 mg/kg) (Fig. 5A ) or low (50 mg/kg) (Fig. 5B) , did not affect the time the rats needed to escape into the dark compartment, as compared to the control group.
The effect of zonisamide administered repeatedly at a dose of 50 mg/kg on emotional memory in the PA
Zonisamide administered for 7 days (Fig. 6A ) and 14 days (Fig. 6B ) at a dose of 50 mg/kg significantly decreased latency to enter the dark compartment in the retention trial, as compared to the control group. During the acquisition trial, no differences between the groups were noted.
Discussion
The complex mechanism of action of zonisamide offers a possibility of using the drug in neurological disorders other than epilepsy. However, it has been reported in clinical trials that the drug might affect verbal fluency, memory, and attention [16, 22] . In our previous pharmacoelectroencephalography study, zonisamide was shown to affect the activity of the hippocampus in rabbits [23] . Hence, the aim of this study was to evaluate the effect of zonisamide on two various types of memory, spatial and emotional, in rats.
The first of the applied behavioral models was the Morris water test, which allows studying of spatial memory in rodents. This test is used to assess cognitive disorders in which the hippocampus plays a key role. The hippocampal CA3 region seems to be crucial for acquisition, memory consolidation, and long-term memory retrieval [24] . Zonisamide administered at a single dose considered in the literature as high (100 mg/kg) impairs memory processes in rats in the MWM test. Deterioration of memory was associated with an increase of the time needed to find the platform and the traveled distance in consecutive days of the study. However, this effect was dose-dependent because it was not observed after the administration of the drug at low dose (50 mg/kg). Zonisamide given repeatedly for two weeks prolonged the time and distance needed to find the platform on the first test day. However, both parameters were reduced on the second test day, which indicates the transient nature of changes. Moreover, memory impairment was not observed in the after-drug phase, i.e., 48 h following administration of the last dose of the zonisamide.
The CA1 hippocampal area is thought to be particularly sensitive to hypoxia, and the consequence of these lesions may be memory impairment. Owen et al. have demonstrated the beneficial effect of zonisamide on spatial memory in gerbil model of global forebrain ischemia. Zonisamide (150 mg/kg i.p.) was administered in the pre-and postischemic phase. Morris water maze test was performed 28 days following ischemia, and it was observed that the animals, both preand posttreated with zonisamide, found the platform faster than the gerbils from the control group. Moreover, the drug given before ischemia significantly reduced pyramidal cell damages in the CA1 region of the hippocampus after 7 and 28 days following ischemia. The authors suggested the neuroprotective effect of zonisamide in hippocampal cells [25] . However, in our study, zonisamide administered at high single dose (100 mg/kg) impaired learning processes in the MWM. This disorder was not observed after the low dose of zonisamide, which indicates that this effect may be dose-dependent. Moreover, different animal model and drug's route of administration have been chosen in our experiment, which may also be relevant. The impact of other novel antiepileptic drugs on spatial memory was investigated, but the results are varied. We observed in our previous study an adverse effect associated with slowing down of learning processes during repeated administration of retigabine in rats. An acute dose of the drug caused temporary or delayed changes in learning processes [26] . In another our study, topiramate administered in a single dose of 120 mg/kg impaired spatial memory in the MWM test in rats; however, these disturbances were not observed after repeated administration of the drug [27] . Other authors have demonstrated that prolonged administration of topiramate caused an improvement [28] or an impairment of spatial memory in the MWM test [29] . Another drug from this group, levetiracetam, did not affect learning processes if given in a single dose (17 or 54 mg/kg i.p.) [30] or impaired the spatial memory when administered in repeated doses [29] .
Cognitive deficits observed in our study may be related to the dysfunction of the hippocampus, a structure closely related to spatial memory. The results of many experimental studies, also using the MWM test, confirm that damage of the hippocampus causes disturbances of both short-term and long-term spatial memory in animals [31] [32] [33] .
Another behavioral test used to achieve the aim of the study was the PA test. It assessed short-term and long-term emotional memory. This type of memory is associated with anxiety, which is generated by an aversive stimulus and involves Pavlovian conditioning based on the acquisition, storage and maintenance of avoidance reactions. It is suggested that this memory depends on the function of the hippocampus and the prefrontal cortex [34] .
Zonisamide administered in single doses, high (100 mg/kg) or low (50 mg/kg), did not impair memory in rats in PA. However, the drug given repeatedly decreased the latency to enter the dark compartment, which indicates a memory disturbance in the animals. This effect occurred both after 7 days and 14 days of the drug administration.
There is no information about the effect of zonisamide on the learning process in PA but the influence of other novel antiepileptic drugs was evaluated in preclinical studies. It has been demonstrated that an acute dose of levetiracetam (17 or 54 mg/kg i.p.) caused adverse effect on emotional memory in mice [30] . Furthermore, levetiracetam and topiramate administered for over 45 days disturbed the acquisition of avoidance reactions in rats [29] .
The available information about the impact of zonisamide on cognitive processes come from clinical trials involving a small number of patients. During a long-term therapy (6-37 months) with zonisamide at a mean daily dose of 225 mg, patients with epilepsy reported varying degrees of cognitive deficits, including memory loss and attention-deficit [22] . The same research team observed in another study memory impairment in some patients with epilepsy who were treated with zonisamide at doses of 100-400 mg/day. Cognitive and mood tests were performed twice during the study: before and after one year of treatment. Zonisamide reduced the frequency of epileptic seizures and did not induce significant mood changes. However, the drug impaired delayed word recall, Trail Making Test Part B, and verbal fluency in some patients, and this effect was dose-dependent [17] . Wandschneider et al. compared the effects of zonisamide, topiramate, and levetiracetam on verbal fluidity and working memory using the functional magnetic resonance imaging (fMRI) language task in patients with focal epilepsy. It has been observed that zonisamide caused the dysfunction of verbal fluidity and working memory. In addition, similar disorders were observed in patients treated with topiramate. The most favorable results were obtained following the administration of levetiracetam, which disturbed the assessed parameters to the smallest degree [35] .
To summarize, the results obtained in this study indicate that zonisamide may impair memory and learning processes in rats; however, the results are varied and depend on the type of memory. It was observed that the drug disturbs the spatial memory mainly if given in a high, acute dose, whereas when administered repeatedly, its effect was noted only in the initial phase of the study. On the other hand, emotion-related memory disturbances were observed only during repeated administration of zonisamide. However, there are some limitations to this study that warrant attention, which are associated with a relatively short time of drug administration and the lack of the assessment of zonisamide's effect on the hippocampal cells. Despite this, it seems that memory disorders after zonisamide administration are associated with the dosage and treatment schedule. This observation is important from the clinical point of view, but further extended studies are needed to determine the risk of cognitive disorders during the zonisamide therapy.
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